Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Deals Hospital

Mabwell Bioscience Extends Research Partnership with Fudan University Cancer Center

Fineline Cube Jan 31, 2024

Mabwell (Shanghai) Bioscience Co., Ltd., (SHA: 688062) has announced the renewal of its strategic research...

Company Drug

Hengrui Pharmaceuticals Scores First-Mover Status with FDA Approval for Generic Astagraf XL

Fineline Cube Jan 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Gilead Increases Stake in Arcus Biosciences and Invests in Anti-TIGIT Program

Fineline Cube Jan 30, 2024

Gilead (NASDAQ: GILD) has strengthened its 2020 collaboration agreement with US-based Arcus Biosciences (NYSE: RCUS)...

Company Drug

Takeda’s Gammagard Liquid Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Jan 30, 2024

The US Food and Drug Administration (FDA) has granted regulatory approval for Takeda’s (TYO: 4502)...

Company Hospital Policy / Regulatory

Shaanxi Province Unveils Ambitious Three-Year Plan to Boost Traditional Chinese Medicine Industry

Fineline Cube Jan 30, 2024

The provincial government of Shaanxi has unveiled the “Three Year Action Plan for Empowering Shaanxi...

Company Drug

AstraZeneca’s Enhertu Receives Priority Review for Expanded HER2-positive Solid Tumor Indication

Fineline Cube Jan 30, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that an indication extension filing for...

Company

MicroPort Scientific Corp. Forecasts 31%-34% Revenue Growth for Subsidiary MicroPort Endovascular in 2023

Fineline Cube Jan 30, 2024

Shanghai-based medical device conglomerate MicroPort Scientific Corp., (HKG: 0853) has issued a revenue and growth...

Company Deals

SANDT Secures Nearly RMB 200 Million to Boost X-ray System Development and Manufacturing

Fineline Cube Jan 30, 2024

SANDT, a Shanghai-based specialist in X-ray systems, has reportedly secured nearly RMB 200 million (USD...

Company Deals

Joincare Pharmaceutical Group Secures USD 100 Million Loan from IFC for Expansion

Fineline Cube Jan 30, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced securing...

Company Deals

South Korean Duo GC Wellbeing and YooYoung Pharmaceutical Target Chinese Filler Market

Fineline Cube Jan 30, 2024

South Korean health and functional food manufacturer GC Wellbeing and YooYoung Pharmaceutical have formed a...

Company Deals

TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline

Fineline Cube Jan 29, 2024

Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on...

Company Drug

Bristol Myers Squibb’s Subcutaneous Opdivo Shows Noninferiority in Phase III ccRCC Trial

Fineline Cube Jan 29, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) this week announced preliminary Phase III data demonstrating that...

Company

Blue Sail Medical Secures RMB 900 Million Investment for R&D and Capacity Expansion

Fineline Cube Jan 29, 2024

Blue Sail Medical Co., Ltd (SHE: 002382) has announced that its wholly owned subsidiary, Blue...

Company Deals

3D Medicines Partners with Sino Cellbiomed to Advance Tumor Immunotherapy Development

Fineline Cube Jan 29, 2024

3D Medicines (HKG: 1244), a China-based oncology specialist, has entered into a partnership with Sino...

Company Deals

Mindray to Acquire 21.12% Stake in APT Medical for RMB 6.652 Billion

Fineline Cube Jan 29, 2024

Mindray (SHE: 300760), a leading China-based medtech firm, has announced plans to acquire a 21.12%...

Company Drug

Johnson & Johnson’s Rybrevant and Lazertinib Filings Accepted for Review by CDE

Fineline Cube Jan 29, 2024

The Center for Drug Evaluation (CDE) has confirmed that Johnson & Johnson’s (J&J, NYSE: JNJ)...

Company Drug

EMA’s CHMP Endorses Bristol Myers Squibb’s CAR-T Therapy Abecma for Multiple Myeloma

Fineline Cube Jan 29, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

Dupixent by Sanofi and Regeneron Approved by FDA for Eosinophilic Esophagitis in Younger Pediatric Patients

Fineline Cube Jan 29, 2024

The US Food and Drug Administration (FDA) has concluded a priority review and granted approval...

Company Deals Drug

Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101

Fineline Cube Jan 29, 2024

Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement...

Company Drug

Apeloa Pharmaceutical Halts Phase III Trial of Salfaprodil for Acute Ischemic Stroke

Fineline Cube Jan 29, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has announced the termination of...

Posts pagination

1 … 407 408 409 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.